Chemistry:Epsametostat
From HandWiki
Epsametostat is an investigational new drug that is being evaluated for the treatment of peripheral T-cell lymphoma. It is a EZH1/EZH2 inhibitor developed by Shanghai Haihe Pharmaceutical Research & Development Co., Ltd.[1][2][3]
References
- ↑ "EZH1/2 as targets for cancer therapy". Cancer Gene Therapy 30 (2): 221–235. February 2023. doi:10.1038/s41417-022-00555-1. PMID 36369341.
- ↑ "Dual-target EZH2 inhibitor: latest advances in medicinal chemistry". Future Medicinal Chemistry 16 (15): 1561–1582. August 2024. doi:10.1080/17568919.2024.2380243. PMID 39082677.
- ↑ "Epsametostat". PatSnap. https://synapse.patsnap.com/drug/fe1d5b1d19364e70b01599f6f2ad1fbb.
 |  |
